Cardiff Oncology annual cash and equivalents
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cardiff Oncology Cash & Equivalents Growth & History (CRDF)
Cardiff Oncology's cash and equivalents was $17.5M for fiscal 2025.
View full Cardiff Oncology company overviewCardiff Oncology annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.5M | −$34.0M | −66.06% |
| 2024 | 2024-12-31 | $51.5M | $29.8M | +137.68% |
| 2023 | 2023-12-31 | $21.7M | $5.3M | +32.47% |
| 2022 | 2022-12-31 | $16.3M | $4.4M | +36.88% |
| 2021 | 2021-12-31 | $11.9M | −$119.0M | −90.88% |
| 2020 | 2020-12-31 | $131.0M | $120.8M | +1184.72% |
| 2019 | 2019-12-31 | $10.2M | −$1.3M | −10.98% |
| 2018 | 2018-12-31 | $11.5M | $3.2M | +39.23% |
| 2017 | 2017-12-31 | $8.2M | −$5.7M | −40.89% |
| 2016 | 2016-12-31 | $13.9M | −$53.6M | −79.38% |
| 2015 | 2015-12-31 | $67.5M | $40.2M | +147.28% |
| 2014 | 2014-12-31 | $27.3M | $1.5M | +5.64% |
| 2013 | 2013-12-31 | $25.8M | $15.0M | +138.79% |
| 2012 | 2012-12-31 | $10.8M | $10.1M | +1444.86% |
| 2011 | 2011-12-31 | $700,374 | $641,671 | +1093.08% |
| 2010 | 2010-12-31 | $58,703 | — | — |
Cardiff Oncology quarterly cash and equivalents
Q4.10
Q4.11
Q1.12
As of Aug 10, 2012
As of Nov 9, 2012
Q4.12
As of May 10, 2013
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.2M | −$1.6M | −14.72% |
| Q1 2026 | 2026-03-31 | $8.5M | −$15.6M | −64.54% |
| Q4 2025 | 2025-12-31 | $17.5M | −$34.0M | −66.06% |
| Q3 2025 | 2025-09-30 | $10.1M | −$2.9M | −22.27% |
| Q2 2025 | 2025-06-30 | $10.8M | −$14.7M | −57.71% |
| Q1 2025 | 2025-03-31 | $24.1M | $5.4M | +29.14% |
| Q4 2024 | 2024-12-31 | $51.5M | $29.8M | +137.68% |
| Q3 2024 | 2024-09-30 | $13.0M | −$2.2M | −14.41% |
| Q2 2024 | 2024-06-30 | $25.5M | $6.1M | +31.66% |
| Q1 2024 | 2024-03-31 | $18.7M | $3.6M | +24.25% |
| Q4 2023 | 2023-12-31 | $21.7M | $5.3M | +32.47% |
| Q3 2023 | 2023-09-30 | $15.2M | −$3.5M | −18.61% |
| Q2 2023 | 2023-06-30 | $19.4M | −$1.6M | −7.61% |
| Q1 2023 | 2023-03-31 | $15.0M | −$5.0M | −25.11% |
| Q4 2022 | 2022-12-31 | $16.3M | $4.4M | +36.88% |
| Q3 2022 | 2022-09-30 | $18.7M | $5.6M | +42.17% |
| Q2 2022 | 2022-06-30 | $21.0M | $10.4M | +98.14% |
| Q1 2022 | 2022-03-31 | $20.1M | $5.4M | +36.76% |
| Q4 2021 | 2021-12-31 | $11.9M | −$119.0M | −90.88% |
| Q3 2021 | 2021-09-30 | $13.2M | −$23.2M | −63.84% |
| Q2 2021 | 2021-06-30 | $10.6M | −$17.2M | −61.88% |
| Q1 2021 | 2021-03-31 | $14.7M | $5.4M | +58.05% |
| Q4 2020 | 2020-12-31 | $131.0M | $120.8M | +1184.72% |
| Q3 2020 | 2020-09-30 | $36.4M | $27.4M | +303.06% |
| Q2 2020 | 2020-06-30 | $27.8M | $17.0M | +157.20% |
| Q1 2020 | 2020-03-31 | $9.3M | −$2.1M | −18.12% |
| Q4 2019 | 2019-12-31 | $10.2M | −$1.3M | −10.98% |
| Q3 2019 | 2019-09-30 | $9.0M | −$6.0M | −40.05% |
| Q2 2019 | 2019-06-30 | $10.8M | −$7.7M | −41.62% |
| Q1 2019 | 2019-03-31 | $11.3M | $4.7M | +70.19% |
| Q4 2018 | 2018-12-31 | $11.5M | $3.2M | +39.23% |
| Q3 2018 | 2018-09-30 | $15.1M | $7.6M | +102.65% |
| Q2 2018 | 2018-06-30 | $18.5M | $10.7M | +137.49% |
| Q1 2018 | 2018-03-31 | $6.7M | −$3.5M | −34.63% |
| Q4 2017 | 2017-12-31 | $8.2M | −$5.7M | −40.89% |
| Q3 2017 | 2017-09-30 | $7.4M | −$15.1M | −67.06% |
| Q2 2017 | 2017-06-30 | $7.8M | −$14.8M | −65.53% |
| Q1 2017 | 2017-03-31 | $10.2M | −$49.8M | −83.02% |
| Q4 2016 | 2016-12-31 | $13.9M | −$53.6M | −79.38% |
| Q3 2016 | 2016-09-30 | $22.6M | −$51.6M | −69.56% |
| Q2 2016 | 2016-06-30 | $22.6M | −$18.7M | −45.32% |
| Q1 2016 | 2016-03-31 | $60.0M | $16.0M | +36.35% |
| Q4 2015 | 2015-12-31 | $67.5M | $40.2M | +147.28% |
| Q3 2015 | 2015-09-30 | $74.1M | — | — |
| Q2 2015 | 2015-06-30 | $41.3M | — | — |
| Q1 2015 | 2015-03-31 | $44.0M | — | — |
| Q4 2014 | 2014-12-31 | $27.3M | $1.5M | +5.64% |
| Q3 2014 | 2014-10-31 | $30.0M | — | — |
| Q2 2014 | 2014-07-31 | $33.6M | — | — |
| Q1 2014 | 2014-04-30 | $21.9M | $13.3M | +154.65% |
| Q4 2013 | 2013-12-31 | $25.8M | $15.0M | +138.79% |
| Q3 2013 | 2013-09-30 | $27.8M | — | — |
| Q2 2013 | 2013-06-30 | $8.3M | — | — |
| As of May 10, 2013 | 2013-05-10 | $8.6M | — | — |
| Q4 2012 | 2012-12-31 | $10.8M | $10.1M | +1444.86% |
| As of Nov 9, 2012 | 2012-11-09 | $7.3M | — | — |
| As of Aug 10, 2012 | 2012-08-10 | $8.3M | — | — |
| Q1 2012 | 2012-03-31 | $586,777 | — | — |
| Q4 2011 | 2011-12-31 | $700,374 | $641,671 | +1093.08% |
| Q4 2010 | 2010-12-31 | $58,703 | — | — |
Cardiff Oncology cash and equivalents trends
Over the last five fiscal years, Cardiff Oncology's cash and equivalents decreased from $131.0M to $17.5M, a change of −$113.5M. The latest reported quarter, Q2 2026, shows $9.2M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiff Oncology source filings ↗